• Ambu posted Q3 2025/26 revenue of DKK 1.64 billion, up 10.3% organically; reported growth was 8.8%.
• EBIT rose to DKK 221 million, lifting the EBIT margin to 13.5%, helped by operating leverage and tariff reclaims.
• Endoscopy Solutions organic growth accelerated to 16%, with Respiratory up 17.1% and Anesthesia & Patient Monitoring up 1.6%.
• Free cash flow before acquisitions increased to DKK 154 million, supported by improved working capital.
• Guidance updated to around 10% organic revenue growth, while the 12%-14% EBIT margin outlook was maintained.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ambu A/S published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.